Pharmatech Associates, a USP company’s Post

*HOT OFF THE PRESS* Citeline Biomedtracker's Dealmaking Quarterly Statistics Q4 2023 During Q4, biopharma merger and acquisition deal value reached $63bn and drew in $75.4bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $3.4bn. Let me know if you want me to send you the pdf. #dealmaking #biopharma #partnering

📰 A recent McKinsey report advises Big Pharma to focus on small, strategic M&A deals for better returns and innovation. Despite a trend in large acquisitions, smaller deals optimize portfolios and foster growth. Key takeaways include retaining talent, leveraging clinical data, and aligning strategic capabilities, particularly in areas like cell and gene therapy. This approach can help navigate patent cliffs and market opportunities. Read more about the strategic insights 👉 https://lnkd.in/dQc6bTAw #mergersandacquisitions #pharmaceuticals #celltherapy #genetherapy #biotechnology #pharmconnect

AbbVie is a great example of why pharma will always be a difficult landscape to navigate. https://lnkd.in/g6CN3PTJ #Altimetry #Research #Business #Investor #Investing #InvestorStrategy #Tech #MarketingStrategy

How to build your AI-enabled drug discovery program

Quality control is a crucial step in any analysis workflow. IGX Platform provides a detailed breakdown of read fates during clone annotation, allowing you to review and export discarded reads. This helps you troubleshoot your data and refine your clonal annotation settings, ensuring reliable and accurate results. Looking to accelerate your biologics discovery? Schedule a personalized demo today: https://lnkd.in/eyQ7vm9N #drugdiscovery #antibodies #qualitycontrol

In the face of global trends, Indiana continues to make its mark across the life sciences landscape, as underscored in the Pharmaceutical and Life Sciences: US Deals 2024 Pipeline Report from PwC. Hoosier companies stand out for making innovative strides, specifically in utilizing AI technology and metabolic advancements, highlighting Indiana's critical role as a key player in the industry's global future. #lifesciences #innovation #healthcareinnovation

Overcome drug development, manufacturing, and regulatory bottlenecks with our integrated tech transfer to new product introduction program. We can take you from onboarding to clinical trials in nine months. Learn more about how we accelerate cell therapies to create healthier lives. Discover how: https://okt.to/vwerRH  #celltherapymanufacturing #cdmo #techtransfer #newproductintroduction

Deals are finally starting to happen

Overcome drug development, manufacturing, and regulatory bottlenecks with our integrated tech transfer to new product introduction program. We can take you from onboarding to clinical trials in nine months. Learn more about how we accelerate cell therapies to create healthier lives. Discover how: https://okt.to/6JLhsq  #celltherapymanufacturing #cdmo #techtransfer #newproductintroduction

With two deals in six days, AbbVie has now inked the 3rd and 4th largest biopharma acquisitions of 2023 so far: Oct. 5: $110 million upfront for Parkinson's disease startup Mitokinin Nov. 30: $10.1 billion for decades-old ADC maker ImmunoGen Dec. 6: $8.7 billion for neuroscience biotech Cerevel Therapeutics CEO Rick Gonzalez hinted at the Chicago-area Big Pharma's appetite for more deals when discussing the ImmunoGen acquisition last Friday when he told analysts: "We have the financial wherewithal to do that if we found another asset that looked like this in neuroscience or anywhere else. We would act on it.” #abbvie #cerevel #pharma #biotech #acquisitions #mergersandacquisitions #dealmaking #drugdevelopment #neuroscienceresearch #schizophrenia #parkinsonsdisease Endpoints News